- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CRISPR Therapeutics AG BDR (C2RS34)
CRISPR Therapeutics AG BDR stock price live, this page displays BVMF C2RS34 stock exchange data. View the C2RS34 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CRISPR Therapeutics AG BDR real time stock price chart below.
What Is the CRISPR Therapeutics AG BDR Stock Price Today?
The CRISPR Therapeutics AG BDR stock price today is 34.60.
What Is the Stock Symbol for CRISPR Therapeutics AG BDR?
The stock symbol for CRISPR Therapeutics AG BDR is "C2RS34."
What Stock Exchange Does CRISPR Therapeutics AG BDR Trade On?
CRISPR Therapeutics AG BDR is listed and trades on the B3 stock exchange.
Is CRISPR Therapeutics AG BDR a Good Stock to Buy?
Determining whether CRISPR Therapeutics AG BDR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the C2RS34 quote. (ISIN: BRC2RSBDR005)
What Is the CRISPR Therapeutics AG BDR Stock Price Today?
The CRISPR Therapeutics AG BDR stock price today is 34.60.
What Is the Stock Symbol for CRISPR Therapeutics AG BDR?
The stock symbol for CRISPR Therapeutics AG BDR is "C2RS34."
What Stock Exchange Does CRISPR Therapeutics AG BDR Trade On?
CRISPR Therapeutics AG BDR is listed and trades on the B3 stock exchange.
Is CRISPR Therapeutics AG BDR a Good Stock to Buy?
Determining whether CRISPR Therapeutics AG BDR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the C2RS34 quote. (ISIN: BRC2RSBDR005)
B3
Currency in BRL
34.60
-0.08(-0.23%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
34.60
34.60
52 wk Range
29.91
40.96
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
34.6034.60
52 wk Range
29.9140.96
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
C2RS34 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Earnings
Latest Release
Nov 02, 2026
EPS / Forecast
-1.15 / --
Revenue / Forecast
12.67M / --
Compare C2RS34 to Peers and Sector
Metrics to compare | C2RS34 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipC2RS34PeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.0x | −1.7x | −0.2x | |
PEG Ratio | −0.73 | −0.01 | 0.00 | |
Price/Book | 3.0x | 0.5x | 2.6x | |
Price / LTM Sales | 199.5x | 4.0x | 2.8x | |
Upside (Analyst Target) | - | 418.7% | 62.7% | |
Fair Value Upside | Unlock | 39.4% | 8.0% | Unlock |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the CRISPR Therapeutics BDR (C2RS34) Stock Price Today?
The CRISPR Therapeutics BDR stock price today is 34.60 BRL.
What Stock Exchange Does CRISPR Therapeutics BDR Trade On?
CRISPR Therapeutics BDR is listed and trades on the B3 Stock Exchange.
What Is the Stock Symbol for CRISPR Therapeutics BDR?
The stock symbol for CRISPR Therapeutics BDR is "C2RS34."
What Is the CRISPR Therapeutics BDR Market Cap?
As of today, CRISPR Therapeutics BDR market cap is 27.41B BRL.
What Is CRISPR Therapeutics BDR's Earnings Per Share (TTM)?
The CRISPR Therapeutics BDR EPS (TTM) is -24.54.
From a Technical Analysis Perspective, Is C2RS34 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has CRISPR Therapeutics BDR Stock Split?
CRISPR Therapeutics BDR has split 0 times.
How Many Employees Does CRISPR Therapeutics BDR Have?
CRISPR Therapeutics BDR has 393 employees.
What is the current trading status of CRISPR Therapeutics BDR (C2RS34)?
As of Nov 05, 2026, CRISPR Therapeutics BDR (C2RS34) is trading at a price of 34.60 BRL, with a previous close of 34.68 BRL. The stock has fluctuated within a day range of 34.60 BRL to 34.60 BRL, while its 52-week range spans from 29.91 BRL to 40.96 BRL.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.